$MOH

This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Torrid Holdings (NYSE:CURV), Arcturus Therapeutics (NASDAQ:ARCT)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Original reporting
Benzinga · Avi Kapoor
Published Oct 24, 2025, 11:57 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 24, 2025, 12:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Torrid Holdings (NYSE:CURV), Arcturus Therapeutics (NASDAQ:ARCT) — source image
Decision brief

The 30-second read

$MOHNeutralLow
01

Why it matters

The overall impact appears limited, with most stocks showing neutral to slight bullish signals, suggesting minimal systemic risk.

02

Market read

The news primarily affects individual stocks with limited immediate impact on broader market indices.

03

What to watch

Fundamental financial health, upcoming earnings reports, and macroeconomic trends could offset analyst sentiment impacts.

Timing: short-term (next 1-2 trading sessions)

Background

Recent analyst downgrades reflect cautious sentiment in certain sectors, possibly influenced by macroeconomic uncertainties.

Company-level read

Ticker impact

$MOHNeutralMedium confidence
Context

Moderately relevant due to somewhat bullish sentiment (score: 0.168638).

Expected impact

Potential minor decline of 1-3% over the short term, contingent on broader market conditions.

Evidence & confidence

The sentiment score indicates a neutral outlook, and the relevance score suggests limited impact. Technical indicators and current valuation are not provided, so the prediction is cautious.

$CURVBullishMedium confidence
Context

Highly relevant given its recent downgrade and somewhat bullish sentiment (score: 0.34645).

Expected impact

Possible short-term price correction of 2-4%, with a potential rebound if fundamentals remain strong.

Evidence & confidence

The mixed signals suggest caution; traders should monitor technical levels and volume for confirmation.

$ARCTNeutralHigh confidence
Context

Moderately relevant with neutral sentiment (score: 0.036951).

Expected impact

Likely minimal impact; price may fluctuate within recent ranges.

Evidence & confidence

Neutral sentiment and low impact probability support a cautious approach.

Market effects

Limited sector-wide impact; healthcare and retail sectors may experience minor volatility due to specific stock downgrades.

No significant regional market effects expected.

Minimal; news pertains mainly to U.S.-based companies and analyst ratings.

Counterpoint

Downgrades may be overreacting, and some stocks could rebound if broader market conditions improve.

Key entities

  • Molina Healthcare

    A managed healthcare company providing Medicaid and Medicare services.

  • Torrid Holdings

    A specialty retailer of women's apparel and intimates.

  • Arcturus Therapeutics

    A biotechnology company focused on RNA medicines.

  • Inspire Medical Systems

    A medical device company specializing in sleep apnea treatment.

  • Barclays PLC

    A multinational investment bank and financial services company.

Related articles

$ARCTMed

Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership

Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.

$ARCTMed

Arcturus Therapeutics Holdings Inc. (ARCT): Results of Operations and Financial Condition

Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrol

$MOHMedAI 8/10

Molina Healthcare Q2 Earnings Call Highlights

Molina Healthcare (MOH) discussed Q2 results on its earnings call. Medicaid MCR was 92.4% in first half, expected to rise to 93.3% in second half. Medicare MCR was 90.7% and full-year Medicare MCR guidance was cut to 92.2%, with 2026 EPS contribution of $0.25. Marketplace MCR pressure led to raised 2026 guidance to 90% and a shift to a $0.75 per share loss. 2027 premium outlook is about $46.5B.

$MOHMedAI 8/10

Molina Healthcare Posts Lower Q2 Earnings, Raises Full-Year Guidance; Stock Down

Molina Healthcare (MOH) reported Q2 2026 revenue of $10.87B, down 5% from Q2 2025, with GAAP net income falling to $60M ($1.19/share) from $255M ($4.75). Adjusted net income was $77M ($1.51). Medical care ratio rose to 92.2%. Despite weaker results, the company raised full-year guidance for GAAP earnings to at least $2.15/share and adjusted to at least $5.25/share.

$MOHMedAI 8/10

Why is Molina Healthcare stock sliding today? By Investing.com

Molina Healthcare (MOH) fell about 9.2% in pre-open trading after reporting Q2 2026 results. Adjusted EPS was $1.51 vs. ~$1.39–$1.40 expected, and revenue was ~$10.87B. Full-year 2026 revenue guidance was ~$42B vs. ~$44.28B consensus, with Medicaid margin “trough year” comments, enrollment pressure, and Florida CMS contract startup costs cited.

$MOHMedAI 8/10

Molina raises full year 2026 guidance after Q2 results

Molina Healthcare reported Q2 2026 adjusted EPS of $1.51, above the $1.39 consensus. Revenue fell to $10.874B from $11.427B a year earlier, while GAAP net income declined to $60M. The company raised full-year 2026 adjusted guidance to at least $5.25 per diluted share and GAAP to at least $2.15. Analysts at RBC, Wells Fargo, and TD Cowen raised price targets for MOH.